Lexicon Q2 2026 earnings: Revenue drops without prior-year license income

Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q2 2026 revenue of $0.7 million, down about 97.6% from $28.9 million a year earlier, while diluted EPS swung to a loss of $0.07 from income of $0.01 per share. The absence of prior-year Novo Nordisk licensing revenue was the main driver of the reversal, while higher clinical-trial spending and a debt-extinguishment charge added pressure. On the pipeline, SONATA-HCM enrollment is complete, with top-line results still expected in Q1 2027.

Core financial results

The year-over-year comparison was heavily affected by licensing revenue. Q2 2025 included $27.5 million recognized under the Novo Nordisk agreement, while Q2 2026 had no licensing or milestone revenue. INPEFA net product revenue also declined to $0.7 million from $1.3 million.

Operating expenses increased as higher external research spending for the SONATA-HCM Phase 3 trial lifted R&D costs. Professional and consulting costs also pushed SG&A modestly higher.

Dollar amounts are in millions except per-share data. Percentage changes are approximate.

Business and pipeline performance

Sotagliflozin for hypertrophic cardiomyopathy: Lexicon completed enrollment in the pivotal Phase 3 SONATA-HCM trial, substantially exceeding its target of 500 patients. The trial includes both non-obstructive and obstructive HCM patients, with non-obstructive patients representing a substantial majority. Top-line results remain scheduled for Q1 2027.

ZYNQUISTA for type 1 diabetes: The third-party-funded STENO1 study is approaching the patient exposure and safety-data requirements previously identified by the FDA. Based on the current data-collection schedule, Lexicon expects to resubmit the New Drug Application in Q4 2026. The company said safety data received to date continue to support resubmission.

LX9851 for obesity and metabolic disorders: Novo Nordisk began a Phase 1 single- and multiple-ascending-dose study in March 2026, with completion expected in Q1 2027. Lexicon has received a $45 million upfront payment and two $10 million clinical-development payments under the partnership. It could receive another $10 million milestone as early as later in 2026, although that payment remains conditional.

International sotagliflozin development: Viatris has secured heart-failure approvals in the United Arab Emirates and Bahrain and submitted applications in several other markets. Regulatory decisions in Australia and Canada are anticipated during 2026, but Lexicon did not quantify potential near-term revenue from these activities.

Profitability, liquidity, and debt

Most of the earnings deterioration occurred at the operating level because licensing revenue disappeared while operating expenses increased. A $4.3 million loss on the early extinguishment of debt widened the net loss further. Stock-based compensation was comparatively stable at $3.3 million, versus $3.2 million in Q2 2025, and therefore did not drive the profit reversal.

Lexicon ended June with $190.6 million in cash and investments. At the end of 2025, it held $96.2 million in cash and investments plus $29.0 million of restricted cash, for a combined $125.2 million. The approximately $65.4 million increase in combined liquidity was financing-led: Lexicon received $96.2 million in net proceeds from selling common and preferred stock in February 2026.

In May, Lexicon entered a $100 million loan facility with Hercules Capital. The initial $55 million tranche was used to repay the previous Oxford Finance facility, meaning it did not represent an equivalent addition to liquidity. A further $20 million is available subject to clinical, regulatory, financial, and timing conditions, while the final $25 million also requires Hercules’ consent.

Risks investors should monitor

• Dependence on licensing and milestone revenue: The Q2 comparison shows how the timing of partner-related revenue can create substantial volatility. Current-quarter product revenue remained limited and fell from the prior-year period.
• Clinical readout risk: Completing SONATA-HCM enrollment removes one execution hurdle, but the program’s value still depends on the Q1 2027 results and subsequent regulatory progress.
• ZYNQUISTA regulatory timing: The planned Q4 2026 resubmission depends on collecting sufficient STENO1 exposure and safety data. Delays could push back the regulatory process.
• Ongoing funding requirements: Lexicon generated a $26.5 million operating loss during the quarter. Its liquidity has improved, but access to the remaining Hercules tranches is subject to milestones, timing requirements, or lender consent.
• Partner execution: Novo Nordisk controls LX9851 development, while Viatris is responsible for sotagliflozin activities outside the U.S. and Europe. Related milestones and market expansion therefore depend partly on third-party execution.

Summary

Lexicon’s Q2 2026 results were dominated by the absence of the prior-year Novo Nordisk licensing contribution, with lower INPEFA sales and higher trial spending adding to the operating loss. Equity financing strengthened liquidity, but the company continues to rely on external capital and milestone-driven economics while advancing its pipeline. The next major operating checkpoints are the planned ZYNQUISTA resubmission in Q4 2026 and Q1 2027 data from SONATA-HCM and the LX9851 Phase 1 program.